Literature DB >> 36181547

An assessment of urethral radiation exposure in the treatment of endometrial and rectal cancers.

Katherine Hines1, Karina Nieto2, William Dezarn2, Kathryn Greven2, Bridget Krol3, Catherine Matthews1, Candace Parker-Autry4.   

Abstract

INTRODUCTION AND HYPOTHESIS: Female survivors of endometrial and rectal cancers have increased risk of urinary incontinence. Survivors with prior radiation therapy are counseled against mesh incontinence surgery. We hypothesize that urethral radiation dose varies based on modality which may influence surgical risks. We aimed to demonstrate urethral radiation dose differences between vaginal brachytherapy (VBT) and external beam radiation therapy (EBRT).
METHODS: This is a retrospective cohort study of women exposed to VBT for endometrial cancer and EBRT for rectal cancer. The urethra was contoured on CT imaging to calculate radiation doses in centigray (cGy). The primary outcome was the percent of treatment radiation dose estimated to be received by the urethra based on the volume dose to 0.2 cc of urethra. Secondary outcomes were point doses to the bladder neck, mid-urethra, and total mean urethral dose. Descriptive statistics described demographic characteristics. Bivariate analyses compared urethral radiation dose based on radiation modality.
RESULTS: Between 2014-2017, 32 women treated were included: 18 with VBT and 14 with EBRT. Mean ± SD urethral volume doses were lower in VBT (1266 cGy ± 533, 42.2% of prescribed treatment dose) compared to EBRT (5051 cGy ± 192, 100.2% of prescribed treatment dose), p < 0.0001. VBT also had significantly lower mean total urethral dose and point doses to bladder neck and mid- urethra compared to EBRT (p < 0.0001).
CONCLUSIONS: The female urethra is exposed to significantly less radiation in VBT compared to EBRT. These data highlight that modality of pelvic radiation should be considered in treatment counseling on urinary incontinence in women.
© 2022. The International Urogynecological Association.

Entities:  

Keywords:  Endometrial cancer; Incontinence; Mesh slings; Radiation therapy; Rectal cancer

Year:  2022        PMID: 36181547     DOI: 10.1007/s00192-022-05363-7

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   1.932


  14 in total

1.  Fractionation in normal tissues: the (α/β)eff concept can account for dose heterogeneity and volume effects.

Authors:  Aswin L Hoffmann; Alan E Nahum
Journal:  Phys Med Biol       Date:  2013-09-13       Impact factor: 3.609

2.  Assessment of dose to functional sub-structures in the lower urinary tract in locally advanced cervical cancer radiotherapy.

Authors:  S Spampinato; L Fokdal; E Marinovskij; S Axelsen; E M Pedersen; R Pötter; J C Lindegaard; K Tanderup
Journal:  Phys Med       Date:  2019-02-13       Impact factor: 2.685

3.  Inverse-planned gynecologic high-dose-rate interstitial brachytherapy: clinical outcomes and dose--volume histogram analysis.

Authors:  Isabelle Thibault; Marie-Claude Lavallée; Sylviane Aubin; Nathalie Laflamme; Eric Vigneault
Journal:  Brachytherapy       Date:  2011-09-08       Impact factor: 2.362

4.  Evaluation and treatment of female stress urinary incontinence after pelvic radiotherapy.

Authors:  Amy D Dobberfuhl
Journal:  Neurourol Urodyn       Date:  2018-10-12       Impact factor: 2.696

5.  MRI-based contouring of functional sub-structures of the lower urinary tract in gynaecological radiotherapy.

Authors:  Sofia Spampinato; Kari Tanderup; Edvard Marinovskij; Susanne Axelsen; Erik M Pedersen; Richard Pötter; Jacob C Lindegaard; Lars Fokdal
Journal:  Radiother Oncol       Date:  2020-01-10       Impact factor: 6.280

6.  A new isoeffect curve for change in dose per fraction.

Authors:  H R Withers; H D Thames; L J Peters
Journal:  Radiother Oncol       Date:  1983-11       Impact factor: 6.280

7.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.

Authors:  R A Nout; V T H B M Smit; H Putter; I M Jürgenliemk-Schulz; J J Jobsen; L C H W Lutgens; E M van der Steen-Banasik; J W M Mens; A Slot; M C Stenfert Kroese; B N F M van Bunningen; A C Ansink; W L J van Putten; C L Creutzberg
Journal:  Lancet       Date:  2010-03-06       Impact factor: 79.321

8.  Computed tomography planned interstitial brachytherapy for recurrent gynecologic cancer.

Authors:  Mark J Amsbaugh; Neal Bhatt; Thomas Hunter; Jeremy Gaskins; Lynn Parker; Daniel Metzinger; Ashley Amsbaugh; Keith Sowards; Moataz El-Ghamry
Journal:  Brachytherapy       Date:  2015-06-16       Impact factor: 2.362

9.  Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer.

Authors:  Malolan S Rajagopalan; Neeta Kannan; Hayeon Kim; Christopher J Houser; Sushil Beriwal
Journal:  Brachytherapy       Date:  2013-03-01       Impact factor: 2.362

10.  Urinary symptoms and impact on quality of life in women after treatment for endometrial cancer.

Authors:  E A Erekson; V W Sung; P A DiSilvestro; D L Myers
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.